Study Stopped
Biogen will stop any further development of the MSPT. The data collected thus far in the MSPT Feasibility Study allow us to answer the primary study objectives that are associated with assessing the feasibility of the MSPT in a clinical care setting.
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
1 other identifier
observational
3,073
6 countries
33
Brief Summary
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2019
Typical duration for all trials
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 22, 2019
CompletedFirst Posted
Study publicly available on registry
April 24, 2019
CompletedStudy Start
First participant enrolled
June 17, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 5, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 5, 2022
CompletedJanuary 30, 2023
January 1, 2023
3.5 years
April 22, 2019
January 27, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
Percentage of Participants Completing All Modules
Baseline to Month 24
Percentage of Participants Completing Each Individual Module
Baseline to Month 24
Percentage of Participants Skipping Modules
Baseline to Month 24
Average Time to Complete the Multiple Sclerosis Performance Test (MSPT)
Baseline to Month 24
Average Time to Complete Individual MSPT Modules
Baseline to Month 24
Frequency of Reasons for Not Completing MSPT Modules
Baseline to Month 24
Frequency Distribution of Demographic Characteristics of Participants Failing to Complete Specific MSPT Modules
Baseline to Month 24
Study Arms (1)
Study Participants
Participants with MS, including CIS will complete the MSPT at their standard of care visits.
Interventions
Administered as specified in the treatment arm.
Eligibility Criteria
Participants with a diagnosis of MS, including CIS will be offered study participation during their standard of care clinic visit or by contacting eligible participants identified from medical records.
You may qualify if:
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with applicable participant privacy regulations
- Diagnosis of MS, including Clinically Isolated Syndrome
- Ability to understand the audio and visual instructions for the test modules
- Visual function, based on the investigator's clinical judgement that does not preclude an ability to interact with the Multiple Sclerosis Performance Test (MSPT).
You may not qualify if:
- Unable or unwilling to provide informed consent
- Participants younger than 18 years of age, unless their parent or legal guardian provides the required signed and dated informed consent and authorization to use confidential health information and the participant provides assent in accordance with national and local subject privacy regulations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Biogenlead
Study Sites (33)
Research Site
Berkeley, California, 94705, United States
Research Site
Los Angeles, California, 90033-5310, United States
Research Site
Aurora, Colorado, 80045, United States
Research Site
Washington D.C., District of Columbia, 20007, United States
Research Site
Atlanta, Georgia, 30309, United States
Research Site
Atlanta, Georgia, 30327, United States
Research Site
Chicago, Illinois, 60008, United States
Research Site
Boston, Massachusetts, 02215, United States
Research Site
Farmington Hills, Michigan, 48334, United States
Research Site
Owosso, Michigan, 48867, United States
Research Site
St Louis, Missouri, 63131, United States
Research Site
Teaneck, New Jersey, 07666, United States
Research Site
Buffalo, New York, 14202, United States
Research Site
Durham, North Carolina, 27710, United States
Research Site
Oklahoma City, Oklahoma, 73104, United States
Research Site
Portland, Oregon, 97225, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Pittsburgh, Pennsylvania, 15212, United States
Research Site
Dallas, Texas, 75390-8806, United States
Research Site
Salt Lake City, Utah, 84103, United States
Research Site
Seattle, Washington, 98122, United States
Research Site
Spokane, Washington, 99208, United States
Research Site
Prague, 12000, Czechia
Research Site
Strasbourg, 67200, France
Research Site
Bari, 70124, Italy
Research Site
Catania, 95123, Italy
Research Site
Milan, 20132, Italy
Research Site
Orbassano, 10043, Italy
Research Site
Roma, 00185, Italy
Research Site
Basel, 4031, Switzerland
Research Site
Bern, 3010, Switzerland
Research Site
Camberley, GU16 7UJ, United Kingdom
Research Site
Oxford, OX3 9DU, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Director
Biogen
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 22, 2019
First Posted
April 24, 2019
Study Start
June 17, 2019
Primary Completion
December 5, 2022
Study Completion
December 5, 2022
Last Updated
January 30, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will share
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/